Karoline V Gleixner

Karoline V Gleixner

UNVERIFIED PROFILE

Are you Karoline V Gleixner?   Register this Author

Register author
Karoline V Gleixner

Karoline V Gleixner

Publications by authors named "Karoline V Gleixner"

Are you Karoline V Gleixner?   Register this Author

42Publications

2094Reads

16Profile Views

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.

Int J Mol Sci 2019 Aug 29;20(17). Epub 2019 Aug 29.

Department of Internal Medicine V (Hematology & Oncology), Medical University of Innsbruck, 1090 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20174233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747233PMC
August 2019

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.

Int J Mol Sci 2019 Jun 18;20(12). Epub 2019 Jun 18.

Division of Allergy and Clinical Immunology, University of Salerno, 84131 Salerno, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20122976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627900PMC
June 2019

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 in Ph+ CML.

Leuk Res 2019 Mar 28;78:36-44. Epub 2018 Dec 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.013DOI Listing
March 2019

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Haematologica 2013 Sep 28;98(9):1450-7. Epub 2013 Mar 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2012.079202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762103PMC
September 2013

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Am J Blood Res 2013 5;3(2):174-80. Epub 2013 May 5.

Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria ; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649810PMC
May 2013

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Exp Hematol 2010 Oct 1;38(10):896-907. Epub 2010 Jun 1.

Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2010.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337971PMC
October 2010

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Exp Hematol 2010 Sep 26;38(9):782-91. Epub 2010 May 26.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2010.05.004DOI Listing
September 2010

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Cancer Res 2010 Feb 9;70(4):1513-23. Epub 2010 Feb 9.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Institute of Immunology, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-2181DOI Listing
February 2010

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Vet Immunol Immunopathol 2009 Dec 18;132(2-4):243-50. Epub 2009 May 18.

Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetimm.2009.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763335PMC
December 2009

Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.

Vet Immunol Immunopathol 2007 Feb 17;115(3-4):320-33. Epub 2006 Nov 17.

Department for Small Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetimm.2006.11.009DOI Listing
February 2007

Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia.

Leuk Lymphoma 2006 May;47(5):897-906

Department of Internal Medicine I, Division of Hematology & Hemostaseology - the Center of Excellence for Clinical and Experimental Oncology (CLEXO), Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190500513652DOI Listing
May 2006

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.

Blood 2006 Jan 27;107(2):752-9. Epub 2005 Sep 27.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology, Institute of Immunology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-07-3022DOI Listing
January 2006